1 / 21

EMERGING ROLE OF STEM CELLS In CARDIOVASCULAR THERAPY

EMERGING ROLE OF STEM CELLS In CARDIOVASCULAR THERAPY. Dr. K. K Haridas MD, DM (Card) DNB (card) Chairman - Department of cardiology – A.I.M.S Cochin 26. Why Rejenuate the Heart Muscle ? . THE PROBLEM : ~ 30 million suffer from heart failure world wide

wilmet
Download Presentation

EMERGING ROLE OF STEM CELLS In CARDIOVASCULAR THERAPY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EMERGING ROLE OF STEM CELLS InCARDIOVASCULAR THERAPY Dr. K. K Haridas MD, DM (Card) DNB (card) Chairman - Department of cardiology – A.I.M.S Cochin 26

  2. Why Rejenuate the Heart Muscle ? • THE PROBLEM : • ~ 30 million suffer from heart failure world wide • ~ 3-4 million develop hear failure every year • CAUSES OF VENTRICULAR REMODELLING • Acute Myocardial Infarction • Cardiomyopathy • Valvular congenital heart disease • OUTCOMES • <1% of all hear failure patients receive donor hearts or assist devices • Annual mortality in hear faisure is 7.5 to 38%

  3. ? The Question Is the heart a terminally differentiated organ ?

  4. ! The Answer ! No.

  5. Historical Evidence – The basis Men the who received sex mismatched donor hearts shows primitive cells bearing Y chromosomes which expressed the markers of cardiomyocytes, smooth muscle cells and endothelial cells (Quainani et al.)

  6. Stem cells Chameleon “ Fountan of Hope” (Genetic) (Micro environment) Trans Differentiation Trans Determination (VCAM/ICAM/MMP) (Cytokines VEGEF) “Homing” ability

  7. Foetal Cardiomyocytes • Ideal cell replacement • Ultrastructural integratian • Good functional improvement of LV Limitations • Limited source / ethics • Immunogenicity • Ischemia sensitivity

  8. Embryonal stem cells Differentiation Early stage : Pacemaker cells Intermediate : Myocardial cell Late : Nodal, His purkinjee cells Note: Day 5 Human blastocyst  inner cell mass • High yield of cardiomyocytes • ? Useful in bio-engineering • Human spare parts factory

  9. LIMITATIONS • ETHICAL ISSUES • IMMUNOGENICITY • TERATOCARCINKOMA • ARRHYTHMOGENESIS

  10. Autologous stem cells • Easy to source • Non immunogenic

  11. Cell Therapy in Failing Heart • GOAL • Transfer of functional myocytes to heart – Improve its function • The DEALS “ Homing of grafted cells” • Engraft into non functional scar • Electromechanical coupling and synchronisation • Neo angiogenesis and myogenesis • Good craft survival • Low immunogenecity • Ethical acceptance • Low oncogenicity • Case of application

  12. Stem cells for myocardial regeneration • HETEROLOGOUS • Fetal cardiomyocytes • Embryonal stem cells • AUTOLOGOUS • Skeletal myoblast • Endothelial progenitors • Bone marrow stem cells

  13. Stem cells therapy • Cardiovascular note • Infarct repair • Cardiomyopathy treatment • End stage coronary artery disease

  14. SKELETAL MYOBLASTS • Satellite cells found in skeletal muscle • Mature into slow twitch fibers • No ultra structural integration • Stretch-ion channel & direct trans-membrane activation • Scaffolding effect – Cell to cell fusion

  15. Limitations of skeletal myoblasts • Arrythmogenesis • Electrical heterogenically • Asynchronous ion channel activity • Post inflammatory • Recutry pathway

  16. Bone marrow stem cells Hemapoeitic Stem cells T-2% Endothelial Progenitor cells <0.05% (Stromal stem cells) (Lin – c Kit (+ve) ; AC 133+) CD 34+ HEART Translocation Transplantation (Endogenous stem cell mobilization) G – CSF GM - CSF CARDIOMYOCYTES Endothelium sm cells

  17. Homing – in of Graft Ischemia ; Hypoxia V CAM I CAM Cytokines Increased vascular permeability VEGF – 2 GCSF SDF – Increased MMP 9

  18. Some Unresolved Issues • Which Cells(s) type ? • Which mode of delivery • Tailored Administration in clinical scenarios • What dose ? • Adjunctive therapy

  19. Some Unresolved Issues • Immunogenecity • How effective / How risky • Optimal timing of therapy • Ethical timing of therapy • Durability of therapy

  20. You see things; and you say “Why” But I dream things that never were; And I say “Why not” G.B. Shaw

  21. In youth we learn In age we understand Mary Von Ebner Eschenbach

More Related